Trump Gets More Credit Than Biden for Lowering Drug Prices: Poll

WASHINGTON — Despite ongoing efforts by the Biden administration, a recent survey indicates that former President Trump is receiving more public credit for initiatives aimed at lowering prescription drug costs. This perception gap highlights the complexities of public opinion and the lasting impact of political messaging, even as new policies take effect.

A new poll by KFF, a non-profit health policy organization, reveals that 41% of Americans believe Trump’s policies are likely to reduce their prescription drug expenses. This belief is sharply divided along party lines, with 79% of Republicans and 11% of Democrats anticipating a positive impact from Trump’s actions. The findings suggest a significant disconnect between public perception and the current policy landscape.

The Awareness Gap: Medicare Negotiation vs. Perceived Trump Impact

The KFF poll also revealed a striking lack of awareness regarding a key component of the Biden administration’s efforts: Medicare’s drug price negotiation program. In September 2024, only 31% of respondents were aware of this program, which allows Medicare to directly negotiate lower drug prices with pharmaceutical companies. In other words a considerably larger proportion of Americans attribute potential cost reductions to Trump’s earlier initiatives than are even aware of the Democrats’ recent legislative achievement.

This disparity isn’t necessarily about the effectiveness of either set of policies, but rather about visibility and messaging. The Trump administration frequently highlighted its efforts to address drug pricing, often through executive actions and public statements. While the impact of those actions was debated, the messaging was consistent and reached a broad audience. The Biden administration’s approach, while potentially more impactful in the long run through systematic negotiation, has faced challenges in gaining similar public recognition.

Trump’s Previous Actions: A Seem Back

During his presidency, Donald Trump pursued several avenues to lower drug prices. These included executive actions aimed at increasing competition and reducing regulatory barriers. He also proposed allowing the importation of drugs from other countries, a move intended to leverage lower prices available elsewhere. Though, many of these initiatives faced legal challenges or were ultimately limited in their scope and impact.

One notable effort was the Trump administration’s attempt to eliminate rebates negotiated between drug manufacturers and pharmacy benefit managers (PBMs). The administration argued that these rebates incentivize PBMs to favor higher-priced drugs, ultimately increasing costs for consumers. However, this proposal also faced opposition from various stakeholders, including the pharmaceutical industry and PBMs themselves.

Medicare Negotiation: How It Works and What It Aims To Achieve

The Inflation Reduction Act, signed into law in 2022, represents a significant shift in the approach to drug pricing. It empowers Medicare to negotiate prices for a select number of high-cost drugs covered under Part B and Part D. The negotiation process began in 2023, with the first negotiated prices taking effect in 2026. The Congressional Budget Office estimates that these negotiations will save Medicare and beneficiaries billions of dollars over the next decade.

The program focuses on drugs that have been on the market for a certain period (typically nine years for small-molecule drugs and thirteen years for biologics) and lack generic or biosimilar competition. The negotiated prices will be available to all Medicare beneficiaries, regardless of their insurance plan. However, the program’s scope is limited, and it does not cover all drugs or all Medicare beneficiaries.

Why Perception Matters: The Role of Political Messaging

The KFF poll underscores the importance of effective communication in shaping public perception of healthcare policy. Even when concrete steps are taken to address issues like drug pricing, their impact can be overshadowed if they are not widely understood or effectively communicated to the public. The Trump administration’s consistent messaging, even if not always supported by demonstrable results, appears to have resonated with a significant portion of the population.

This highlights a broader challenge for policymakers: translating complex policy changes into tangible benefits that are easily understood by voters. The Biden administration faces the task of increasing public awareness of the Medicare negotiation program and demonstrating its positive impact on drug costs. This will require a sustained and targeted communication strategy.

Looking Ahead: Ongoing Efforts and Future Considerations

The debate over drug pricing is far from over. Both the Trump and Biden administrations have recognized the need to address this issue, but their approaches have differed significantly. The Medicare negotiation program represents a major step forward, but It’s only one piece of the puzzle. Other potential solutions include promoting generic and biosimilar competition, addressing patent abuses, and reforming the PBM system.

Further research is needed to fully understand the impact of these various policies and to identify the most effective strategies for lowering drug costs. Ongoing monitoring of the Medicare negotiation program will be crucial, as will continued efforts to educate the public about the available options for accessing affordable medications. The KFF continues to track public opinion on these issues, providing valuable insights into the evolving landscape of drug pricing and healthcare policy.

The future of drug pricing will likely involve a combination of policy changes, market forces, and public pressure. The current perception gap, as highlighted by the KFF poll, serves as a reminder that effective policy implementation requires not only sound strategies but also clear and consistent communication.